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at 28.41% and 46.32% resistance to macrolides; 42.33%
of isolates were MRSA; Enterococcus faecalis had a
level of 14.49% resistance to ampicillin; Pseudomonas
spp. showed a 47.46% level of ﬂuoroquinolones-resistance
and a 36.11% level of carbapenem-resistance (imipenem
and/or meropenem); 24.81% of Enterobacteriaceae were
ﬂuoroquinolone-resistant and 23.11% were resistant to third
generation cephalosporins; 73.07% of Acinetobacter isolates
were carbapem-resistant; Escherichia coli had the following
spectrum of resistance: 24.21% ﬂuorquinolone-resistance
and 15.3% third generation cephalosporin-resistance.
Conclusions: The resistance levels are quite high, in
accordance with the EARSS reported Romanian data, and in
some situations even higher. Limitations of this study could
be due to technical problems or statistical inaccuracy. A
more thorough and clear research of susceptibility testing is
mandatory and more data is necessary in order to elaborate
valid treatment guidelines.
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Background: Empirical broad-spectrum antibiotic therapy
remains the cornerstone of treatment for febrile
neutropenic patients. The aim of this study was to evaluate
the efﬁcacy of ceftazidime plus Amikacin as empirical
therapy in patients with febrile neutropenia.
Methods: Non-randomized prospective study conducted in
the national center of hematology from May 2009 to
March 2010. Adult patients treated for acute leukemias and
presented with febrile neutropenia included in this study.
Patients received ceftazidime 2g twice daily plus amikacin
at a dose of 15mg/kg twice daily (maximum 20mg/kg).
If fever persisted, a second-line therapy with meropenem
was administered. Teicoplanin was given for Gram-positive
isolates or for unremitting fever after 48 hours.
Table 1. Clinical characteristics of patients and febrile episodes
Patients Febrile episodes
Total no. 54 89
Median age, years (range) 24 (15 72)
Gender (male/female) 51/38
Cause of neutropenia, no. (%)
Acute lymphoblastic leukemia 22 (40.7) 37 (41.5)
Acute myeloid leukemia 32 (59.2) 52 (58.4)
G-CSF added, no. (%)
Yes 0(92.5)
No 4 (7.5)
Prophylaxis antibiotic, no. (%)
Yes 51 (94.4)
No 3 (5.6)
Median ANC at presentation, ×109 (range) 0.10(0.00.- 0.50)
Episode classiﬁcation, no. (%)
Microbiologically documented 19 (21.3)
Clinically documented 27 (30.3)
Fever of unknown origin 43 (48.3)
G-CSF: granulocyte-colony stimulating factor; ANC: absolute neutrophil count.
Results: 89 episodes of fever and neutropenia were
evaluated in 54 patients. 19 (21.3%) of episodes were
documented microbiologically, while 27 (30.3%) of episodes
were clinically documented, and 43 (48.3%) were fever
of unknown origin. 35 (39.3%) of total episodes showed
response to ceftazidime plus amikacin, while 54 (60.6%)
showed no response and required treatment modiﬁcation.
The predominant pathogens isolated in this study were
Gram-negative organisms (63.1%).
Conclusion: Ceftazidime plus amikacin is not effective as
an initial empirical therapy for adult patients with febrile
neutropenia.
Table 2. Causative microorganisms isolated from 19 febrile episodes
Microorganism No. of
isolates
Ceftazidime
sensitive
Amikacin
sensitive
Escherichia coli 3 1/3 3/3
Staphylococcus aureus 2 1/3 2/3
Pseudomonas aeruginosa 3 2/3 3/3
Klebsiella pneumoniae 1 1/1 1/1
Enterobacter spp. 2 1/2 2/2
Bacillus 1 1/1 1/1
Streptococcus pneumoniae 2 1/2 1/2
Enterococcus faecalis 1 1/1 1/1
MRSE 1 n/a n/a
Acinetobacter spp. 1 1/1 1/1
Moraxella 2 2/2 2/2
NA: not available; MRSE: methicillin-resistant Staphylococcus epider-
midis.
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Background: Over the last decades, methicillin resistant
Staphylococcus aureus (MRSA) had caused major problems
in the hospitals throughout the world. Cajanus cajan,
Kigelia africana, Plumbago zeylanica are medicinal plants
commonly prescribe by traditional medical practitioner in
Nigeria for treatment of infectious diseases, they were
tested in vitro for their anti-MRSA properties against ﬁve
clinical isolate of MRSA. The bacterial cultures used were
strains isolated from patients.
Objectives: The objective of the study is to conﬁrm the
activity of these medicinal as claimed by the traditional
medical practitioner.
Methods: Fresh plant materials were collected and air
dried; methanol extracts of the powdered plants samples
were obtained by standard methods. Diameter zone of
inhibition was used as a measure of the anti-MRSA properties
using Gentamicin and Oﬂoxacin as reference standard in
Agar diffusion assay.
Results: The result revealed that the crude extracts of the
leaf of Cajanus cajan and the root of Plumbago zeylanica
were effective against MRSA with MIC as low as 3.98mg/ml
and 1.58mg/ml respectively while the methanol extract of
the bark of Kigelia africana showed no signiﬁcant activity
against MRSA. Partitioning of the two active plant extracts
into solvents of varying degree of polarity indicates that,
the activities of the two plants lies more in their polar and
moderately polar constituent.
Conclusion: The result of this study offers a scientiﬁc basis
for the use of the extracts of Cajanus cajan and Plumbago
zeylanica against MRSA associated diseases.
